Press Releases

GAP Experts Share Poster Presentations at Alzheimer’s Association International Conference (AAIC) Washington D.C., July 9, 2026- The Global Alzheimer’s Platform Foundation®, (GAP) will have two poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC) being held in Londong July 12 through July 15. All posters are in the Exhibit Hall in Excel London, Royal Victoria Dock, 1 […]

Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias  Washington D.C., July 8, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Taudia to the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of […]

Washington D.C., July 1, 2026- Elevance Health, formerly Anthem Inc., updated their medical policy, to allow for blood-based biomarker testing for the detection and diagnosis of Alzheimer’s disease, making Elevance Health one of the first major payors to outline coverage criteria. GAP President John Dwyer said, “GAP applauds the decision by Elevance Health to explicitly endorse […]

Free Memory Screenings Offered Across the Country during Alzheimer’s and Brain Awareness Month WASHINGTON, DC (June 4, 2026)- Alzheimer’s research sites across the country are recognizing Alzheimer’s and Brain Awareness Month by offering free memory screenings for adults age 55 and older. Throughout June, researchers are raising awareness about brain health and the importance of learning about […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data Washington D.C., May 28, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine, access to analyze Bio-Hermes-001 samples to investigate the potential for circular RNA […]

Free Memory Screenings Offered to Promote Importance of Brain Health WASHINGTON, DC (May. 20, 2026)- Alzheimer’s research sites across the country are honoring National Clinical Trials Day by offering free memory screening for adults age 55 and older.  National Clinical Trials Day recognizes the progress made in developing treatments and therapies, advances which could not have been […]

Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve  diagnosis of Alzheimer’s disease and dementias.  Washington D.C., May 18, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce the continued expansion of the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse […]

Siemens Healthineers joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias  Washington D.C., Apr. 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare, to the Bio-Hermes-002 study. This collaboration will enhance this unique, […]

Tampa, FL, Mar 25, 2026—  Axiom Brain Health (Axiom) is pleased to announce Dr. Susan Steen will be honored by the Alzheimer’s Association – Florida Gulf Coast Chapter at the Inspire, Imagine, and Hope Gala on Friday, March 27, 2026, at The Gathering @ Armature Works in Tampa. “I am delighted to receive this honor from the […]

The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas WASHINGTON, DC (Feb. 27, 2026) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2025 National Citizen Scientist Awards® elevated honorees. GAP’s Citizen Scientist Awards (CSA) acknowledge the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases.  This year’s award […]

Researchers and Executives from almost 50 clinical trial sites, pharmaceutical companies and technology partners to collaborate on improving research & treatment options Las Vegas., Feb. 20, 2026- From February 25 through February 27 the Global Alzheimer’s Platform Foundation® (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s and neurodegenerative clinical trials in pursuit of a cure, will convene nearly 250 representatives from […]

“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact.  A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with […]

“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin […]

Washington D.C., Jan 20, 2026, The Global Alzheimer’s Platform Foundation® (GAP) applauds the House and Senate Committees on appropriations releasing their final bipartisan FY2026 Labor–Health and Human Services–Education appropriations bill which increases funding for Alzheimer’s disease and other dementia research.     “Congress’s bipartisan approval of increased funding for neurodegenerative research sends a powerful message to the millions of […]

Spear Bio joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias  Washington D.C., Jan 12, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform […]

Washington D.C., Jan 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical […]

Collaboration to Improve Access to Study for Alzheimer’s Disease Las Vegas, Nev. – Dec. 23 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers […]

The Global Alzheimer’s Platform Foundation® (GAP) today issued a statement following the release of top-line updates from two Alzheimer’s clinical trials: Recently, developments in two important Alzheimer’s clinical research studies were reported. The two studies were: Novo Nordisk’s Phase 3 EVOKE and EVOKE+ trials evaluating oral semaglutide, and Johnson & Johnson’s Phase 2b trial evaluating the […]

International non-profit Global Alzheimer’s Platform Foundation expands research network in California to improve access to research opportunities Washington D.C., Oct. 14, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Sun Valley Research Center (SVRC) a private clinical research organization based in Imperial, California, to its global network of over 100 best-in-class research sites. SVRC […]

Strategic collaborations are key to improving the pace and access to research.  Undiagnosed and Overlooked  Everyone knows someone impacted by Alzheimer’s disease, as it affects an estimated 55 million people worldwide. What is often overlooked is the shocking number of people who remain undiagnosed due to fear of going to a doctor, lack of access […]

Mission Viejo, Aug 12, 2025— Brain health is being taken on the road in Mission Viejo with a Mobile Research Unit that will tour the West Coast to improve accessibility to brain health education and services. The Mobile Research Unit made its debut on August 9 with a ribbon cutting with The Healthy Brain Clinic […]

Florida Mobile Research Unit Launched with Axiom Brain Health at New Mt. Zion Baptist Church     Tampa, FL Aug 6, 2025— Brain health is being taken on the road in Tampa as Axiom Brain Health launched a new Florida-based mobile research unit that will tour the state, to improve accessibility to brain health education and […]

Data from Most Deeply Characterized Cohort Across Alzheimer’s Disease Released byGlobal Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative Washington D.C., July 31, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated from the Bio-Hermes-001 study are now publicly available. This release […]

Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research. This partnership will leverage the combined expertise of GAP’s Site Alliance […]